A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Refractory B-cell Acute Lymphoblastic Leukemia, Childhood Clinical Trial

Official title:
A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma

Status Recruiting

Clinical Trial Summary

This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Lymphoid
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood
Relapsed/Refractory B-cell Lymphoma, Childhood

Clinical Trial Details

NCT number	NCT04204161
Study type	Interventional
Source	Shenzhen BinDeBio Ltd.
Contact	Yang Zhonghua
Phone	18938688105
Email	zh.yang@bindebio.com
Status	Recruiting
Phase	Phase 1
Start date	October 8, 2019
Completion date	October 8, 2024

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03265106` - A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects	Phase 1/Phase 2